FINWIRES · TerminalLIVE
FINWIRES

グラス・ルイス論争の警告: カヒヤ・マタ・サラワク州

By

-- グラス・ルイスは、5月25日に開催されるカヒヤ・マタ・サラワク(KLSE:CMSB)の年次株主総会に先立ち、株主向けに懸念事項に関する警告を発令した。 この警告は、取締役で元副会長のマフムード・アブ・ベキル・タイブ氏が同社および他の取締役を相手取って起こした訴訟に関するものである。 タイブ氏は、取締役会および委員会の会議から排除され、議事録や財務情報の閲覧も認められなかったと主張している。 同社は、排除の理由は進行中の訴訟手続きにおける利益相反のためだと説明している。 グラス・ルイスは、この問題は内部ガバナンスの摩擦を示しており、取締役会の安定性、有効性、および監督体制に疑念を生じさせると指摘している。 警告の根拠は、関連するメディア報道と著しいガバナンス慣行にあり、取締役会の有効性と監督体制の問題に該当する。

Related Articles

Equities

Berenberg Adjusts Estimates for Galp Energia After 'Solid' Q1 Results; Hold Rating Maintained

Berenberg updated its earnings forecasts for Galp Energia (GALP.LS) after the Portuguese energy company reported its first-quarter results."Galp reported a solid set of results for Q126 on 27 April from an operational point of view, and beat consensus EBITDA expectations, although this was offset by some cash flow adjustments in the period. Delivery of the important Bacalhau project (Brazil) appears to be ahead of expectations, and, after a strong Q1 in the refining business, Galp is moving towards confirming the terms of its downstream merger with Moeve. In the earnings call, the company indicated that its 2026 guidance is now likely out of date given the macro backdrop, and that it may update its FY26 outlook in the Q2 results. We leave our Hold rating and EUR20 price target unchanged," the research firm said Wednesday.Against this backdrop, the research firm increased its 2026 EBITDA assumption by 3%, while cutting its cash flow from operations and free cash flow estimates by 4% and 3%, respectively, to account for a recent 320 million-euro renewable acquisition and other liquidity adjustments.Meanwhile, analysts maintained their share repurchase projection for 2026 at 250 million euros, while boosting their 2027 forecast to 455 million euros, which is 10% above consensus. Berenberg's EPS estimates for 2026 through 2028 were also revised upwards.

$GALP.LS
Asia

Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in China

Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.

$HKG:2696
Equities

BP Confirms Preliminary Offshore Exploration Agreement With Venezuela

BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.

$BP.L